Searchable abstracts of presentations at key conferences in endocrinology

ea0022p620 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Epidemiology of acromegaly in Italy

Malchiodi Elena , Arosio Maura , Borraccino Alberto , Reimondo Giuseppe , Zaggia Barbara , Montefusco Laura , Maria Colao Anna , Terzolo Massimo

Aim of this study is to present preliminary epidemiological data on a population of 1512 acromegalic patients attending 22 tertiary centers in Italy from 1980 to 2002. At our knowledge this is the first large–scale epidemiological Italian study on acromegaly. Gender was 624 (41.2%) men and 888 (58.8%) women. Mean age at diagnosis was 45±13 years, 43±13 for men and 47±13 for women. Median estimated duration of acromegaly before diagnosis was 74 months (range...

ea0022p618 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood

Reimondo Giuseppe , Palmas Enrico , Vannelli Silvia , Bellone Jaele , Bellone Simonetta , Matarazzo Patrizia , Gasco Valentina , Borraccino Alberto , Migliaretti Giuseppe , Cavallo Franco , Ravaglia Aldo , Angeli Alberto , Aimaretti Gianluca , Terzolo Massimo

The potential side effects of the rhGH therapy have been evaluated only during treatment and the accessible databases have been developed as a post-marketing surveillance only by the Companies distributing rhGH. Aim of the present study was to evaluate health consequences (metabolic diseases and/or malignancies) in adults previously treated with rhGH during childhood. We recruited 284 patients (median age at diagnosis 12 years, range 3–17) who underwent rhGH treatment bet...